Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28650837 | 1.00 | NR1H2 (0.41) | NR1H2KMT2AL3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL22324118 | 0.86 | CHRM2 (0.40) | KMT2AL3MBTL1SLC6A4SLC6A3CHRM2 | |
| SCHEMBL16237040 | 0.86 | CHRM2 (0.40) | KMT2AL3MBTL1SLC6A4SLC6A3CHRM2 | |
| SCHEMBL16237439 | 0.83 | CHRM2 (0.35) | NR1H2KMT2AL3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL16237411 | 0.82 | CHRM2 (0.40) | KMT2AL3MBTL1SLC6A4SLC6A3CHRM2 | |
| SCHEMBL22323735 | 0.82 | CHRM2 (0.40) | KMT2AL3MBTL1SLC6A4SLC6A3CHRM2 | |
| SCHEMBL16249858 | 0.80 | THRB (0.38) | NR1H2KMT2AL3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL7688348 | 0.79 | CHRM2 (0.36) | KMT2AL3MBTL1SLC6A4SLC6A3CHRM2 | |
| SCHEMBL7683672 | 0.78 | THRB (0.41) | NR1H2KMT2AL3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL16249881 | 0.76 | SLC6A4 (0.42) | NR1H2KMT2AL3MBTL1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113661162-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2021-11-16 | — | — | CN | disclosed |
| US-9758530-B2 | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160122363-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9266904-B2 | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140343032-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343032-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2D6, TPMT | NR1H2 376/4885KMT2A 2735/4885L3MBTL1 1355/4885 |
| US-20160122363-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2D6, TPMT | NR1H2 376/4885KMT2A 2735/4885L3MBTL1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.